A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

There is an unmet need for effective therapies for advanced systemic mastocytosis (advSM). CD30 is expressed on the surface of neoplastic mast cells (MC) in more than 50% of patients with advSM. Brentuximab vedotin (BV) is a CD30-directed antibody-drug conjugate with preclinical evidence supporting...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood Adv
Huvudupphovsmän: Gotlib, Jason, Baird, John H., George, Tracy I., Langford, Cheryl, Reyes, Isabel, Abuel, Justin, Perkins, Cecelia, Schroeder, Kurt, Bose, Prithviraj, Verstovsek, Srdan
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2019
Ämnen:
Clinical Trials and Observations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693006/
https://ncbi.nlm.nih.gov/pubmed/31350306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000152
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk